3 signs shares in ResMed Inc are a long-term bargain

Shares in breathing device maker ResMed Inc. (ASX: RMD) are down nearly 9% so far in 2014, compared to a minor 0.8% increase in the S&P / ASX 200 Index (Index: ^AXJO) (ASX: XJO).

In my view this weakness could be a great opportunity to buy or top up on ResMed shares which could turn out to be a long-term bargain. Here are three reasons why:

1. ResMed is still buying its own shares

Last week ResMed’s board of directors approved a new share buyback program granting the company approval to repurchase up to 20 million shares on the open market. This represents around 14% of outstanding shares and is a continuation of the company’s long-term capital management plan.

The impact of the program is to increases earnings per share, as well as the company’s share price. ResMed holds around U.S. $876 million in cash and cash equivalents and it can be an effective way to return some of that cash to shareholders.

2. It could be cheaper than its competitor

With a price-to-earnings (p/e) ratio of around 20, at a high level ResMed appears to offer better current value than Kiwi competitor, Fisher & Paykel Healthcare Limited (ASX: FPH), with a comparatively high p/e ratio of 27.

Obviously this fails to take into account expected growth and last month FPH announced an increase to expected net profit for the full year. However ResMed has grown net profit by 35% in the last three years and this is likely to continue per reason three below.

3. Long-term demographics are in its favour

A global increase in the ‘greying population’, rising obesity and increasing global healthcare spending will help to play into the hands of ResMed in the years to come.

Mick Farrell, ResMed’s chief executive officer, noted in the company’s recent quarterly update the strong prospects for growth from new product launches: “Opportunities for growth remain in sleep, respiratory care, and cardiorespiratory markets in all geographies.”

Foolish takeaway

Behind ResMed’s falling price is a company with strong long-term growth prospects and a capital management plan to return value to shareholders. If revenue and earnings growth can continue, the current price could turn out to be a long-term bargain.

The top ASX pick you've never heard of...

Top Motley Fool analysts just identified their #1 ASX pick for 2014, a small-cap stock that could be poised for big gains (and offers a fat, fully franked dividend!). Discover all the details now, including the name and code, in this FREE investment report, "The Motley Fool's Top Stock for 2014."

Motley Fool contributor Regan Pearson does not own shares in any of the companies mentioned in this article.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.